{"gene":"VEGFB","run_date":"2026-06-11T09:02:06","timeline":{"discoveries":[{"year":1998,"finding":"VEGF-B binds selectively to VEGF receptor-1/Flt-1, with binding blockable by excess VEGF indicating at least partially overlapping binding sites. Mutating putative binding determinants Asp63, Asp64, and Glu67 to alanine reduced but did not abolish Flt-1 affinity. Binding of VEGF-B to its receptor on endothelial cells leads to increased expression and activity of urokinase-type plasminogen activator and plasminogen activator inhibitor-1.","method":"Receptor binding assay, site-directed mutagenesis, endothelial cell functional assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — receptor binding with mutagenesis plus functional downstream assay in one study; foundational paper replicated in concept by numerous subsequent studies","pmids":["9751730"],"is_preprint":false},{"year":1998,"finding":"VEGF-B is not regulated by hypoxia, Ras oncoprotein, or mutant p53 (stimuli that potently induce VEGF-A), and its mRNA is highly stable (T1/2 > 8 h), distinguishing its regulation from VEGF-A and VEGF-C.","method":"Northern blot, mRNA stability assay in cultured cells","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean cell-based assays with multiple stimuli, single lab","pmids":["9188862"],"is_preprint":false},{"year":1996,"finding":"The VEGF-B186 isoform arises by alternative splicing introducing a frameshift, is secreted, undergoes O-linked glycosylation post-secretion (25 kDa → 32 kDa), is expressed as a disulfide-linked homodimer, and forms heterodimers with VEGF-A when co-expressed.","method":"cDNA cloning, transfection, SDS-PAGE, biochemical characterization","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct biochemical characterization with multiple orthogonal methods (SDS-PAGE, glycosylation analysis, co-expression for heterodimerization)","pmids":["8702615"],"is_preprint":false},{"year":2000,"finding":"Vegfb knockout mice have smaller hearts and dysfunctional coronary vasculature with impaired recovery from experimentally induced myocardial ischemia, establishing a role for VEGF-B in coronary vasculature development and/or function.","method":"Gene knockout mouse model, cardiac phenotyping, coronary occlusion model","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean KO with defined cardiac phenotypic readout; replicated and extended by subsequent studies","pmids":["10666423"],"is_preprint":false},{"year":2008,"finding":"VEGF-B inhibits apoptosis via VEGFR-1-mediated suppression of proapoptotic BH3-only protein genes and other apoptosis/cell-death-related genes (including p53 and caspase family members); neuronal rescue in retinal and brain models was confirmed in vivo.","method":"Gene expression profiling, real-time PCR, in vivo neuroprotection models (retinal degeneration, stroke), VEGFR-1-dependent mechanism","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple cell types, in vivo models, receptor-dependency demonstrated; single lab but orthogonal methods","pmids":["18259607"],"is_preprint":false},{"year":2009,"finding":"VEGF-B is dispensable for blood vessel growth but critical for vascular cell survival (endothelial cells, pericytes, smooth muscle cells, vascular stem/progenitor cells); its vascular survival effect is mediated through both NRP-1 and VEGFR-1 by regulating pro-survival gene expression.","method":"Multiple animal models, multiple vascular cell type assays, in vivo choroidal/retinal neovascularization targeting","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple cell types and animal models, two receptors identified, replicated concept across publications","pmids":["19369214"],"is_preprint":false},{"year":2009,"finding":"VEGF-B186 isoform protects primary motor neurons against degeneration via the tyrosine kinase activity of Flt1 (VEGFR-1) expressed on motor neurons; intracerebroventricular delivery prolonged survival of mutant SOD1 rats. Vegfb-knockout mice crossed with mutant SOD1 mice developed more severe motor neuron degeneration.","method":"Primary motor neuron culture, Vegfb/SOD1 double-mutant mice, intracerebroventricular delivery, kinase inhibitor experiments","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vitro + in vivo epistasis + receptor tyrosine kinase dependency established in one study","pmids":["18923022"],"is_preprint":false},{"year":2009,"finding":"VEGF-B186 activates VEGFR-1 on cardiomyocytes (which also express VEGFR-2 and neuropilin-1; VEGFR-1 is up-regulated under hypoxia/oxidative stress), elicits an antiapoptotic effect, and induces a compensatory hypertrophic gene expression profile (activation of αMHC, repression of βMHC/skeletal α-actin, increase of SERCA2a, RYR, PGC1α), preserving cardiac function after myocardial infarction.","method":"AAV-mediated gene delivery in rats, cardiomyocyte culture, gene expression profiling, in vivo myocardial infarction model","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vitro + in vivo, receptor identified, gene expression profile established, functional cardiac readout","pmids":["20019242"],"is_preprint":false},{"year":2011,"finding":"VEGF-B and its receptor FLT1 are expressed in dorsal root ganglion neurons; VEGF-B186 maintains mitochondrial membrane potential, reduces neuronal stress, and protects against retrograde degeneration of sensory neurons via direct FLT1-mediated effects on neurons (not surrounding vasculature).","method":"DRG primary cultures from Vegfb/Flt1 KO mice, paclitaxel neuropathy model, neuronal FLT1 transgenic overexpression, gene transfer, recombinant protein","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic models (KO, transgenic OE), in vitro + in vivo, receptor identified, mitochondrial readout","pmids":["21248239"],"is_preprint":false},{"year":2010,"finding":"VEGF-B controls endothelial uptake and transport of fatty acids in heart and skeletal muscle. Vegfb knockout in diabetic db/db mice prevented ectopic lipid deposition and increased muscle glucose uptake; pharmacological VEGF-B inhibition restored insulin sensitivity in high-fat-diet rats.","method":"Vegfb genetic knockout in db/db mice, antibody pharmacological inhibition, glucose tolerance/insulin sensitivity assays, in vivo imaging","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic and pharmacological inhibition in multiple rodent models with defined metabolic readouts; published in Nature, independently replicated concept","pmids":["23023133"],"is_preprint":false},{"year":2016,"finding":"VEGFB binding to VEGFR1 activates the VEGF/VEGFR2 pathway and increases capillary density, tissue perfusion, and insulin supply/signaling in adipose tissue; endothelial Flt1 deletion enhances VEGFB effect and activates thermogenic program in subcutaneous adipose tissue.","method":"Vegfb gene transduction in mice, endothelial Flt1 conditional knockout, metabolic and vascular phenotyping","journal":"Cell metabolism","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic gain- and loss-of-function with multiple orthogonal readouts, receptor pathway identified","pmids":["27076080"],"is_preprint":false},{"year":2016,"finding":"PGC-1α together with estrogen-related receptor α (ERR-α) transcriptionally regulates Vegfb expression in skeletal muscle; PGC-1α overexpression increases Vegfb, leading to increased muscular lipid accumulation that is normalized by Vegfb ablation.","method":"Muscle-specific PGC-1α transgenic mice, Vegfb knockout crosses, chromatin/transcription factor analysis, metabolic phenotyping","journal":"Diabetes","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis with double-mutant rescue, transcriptional regulator identified","pmids":["26822083"],"is_preprint":false},{"year":2017,"finding":"Renal VEGF-B expression correlates with severity of diabetic kidney disease; inhibiting VEGF-B signaling in DKD mouse models reduces renal lipotoxicity, re-sensitizes podocytes to insulin signaling, and prevents renal dysfunction.","method":"DKD mouse models, anti-VEGF-B antibody treatment, renal lipid/insulin signaling assays","journal":"Cell metabolism","confidence":"High","confidence_rationale":"Tier 2 / Strong — pharmacological inhibition in multiple mouse models with mechanistic readouts (lipid, insulin signaling), published in Cell Metabolism","pmids":["28190774"],"is_preprint":false},{"year":2018,"finding":"VEGF-B is a potent antioxidant; it upregulates numerous antioxidative genes, particularly Gpx1. Loss of Gpx1 activity largely diminished the antioxidative effect of VEGF-B. The antioxidant function is mediated mainly by VEGFR1; Vegfb deletion causes retinal degeneration, and VEGF-B treatment rescues retinal cells in a retinitis pigmentosa model.","method":"Vegfb gene deletion in mice, retinitis pigmentosa model, gene expression profiling, Gpx1 loss-of-function, VEGFR1-dependency assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic models (Vegfb KO, Gpx1 KO) with epistasis, in vivo retinal model, VEGFR1-dependency established","pmids":["30249667"],"is_preprint":false},{"year":2020,"finding":"VEGF-B signaling impairs recycling of low-density lipoprotein receptor (LDLR) to the plasma membrane, reducing cholesterol uptake and membrane cholesterol loading, which decreases GLUT1-dependent endothelial glucose uptake; inhibiting VEGF-B in vivo reconstitutes membrane cholesterol levels and restores glucose uptake.","method":"VEGF-B signaling in endothelial cells, LDLR trafficking assay, membrane cholesterol measurement, GLUT1 functional assay, in vivo inhibition","journal":"EMBO reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — mechanistic pathway (VEGF-B→LDLR recycling→cholesterol→GLUT1) established with multiple orthogonal in vitro and in vivo methods","pmids":["32449307"],"is_preprint":false},{"year":2023,"finding":"VEGF-B inhibits NAFLD development by blocking lipolysis in white adipose tissue (WAT); adipocyte-specific VEGF-B overexpression worsens NAFLD while adipocyte-specific knockout reduces it, acting through regulation of hormone-sensitive lipase activity and WAT insulin resistance.","method":"AdipoqCre conditional VEGF-B transgenic and floxed knockout mice, NAFLD model, neutralizing antibody, lipolysis assay, hormone-sensitive lipase activity","journal":"Journal of hepatology","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-type-specific gain- and loss-of-function with mechanistic effector (HSL) identified, pharmacological validation","pmids":["36717026"],"is_preprint":false},{"year":2025,"finding":"VEGF-B186 promotes cardiac angiogenesis via RGD-binding integrins (ITGAV and ITGA5) as newly identified receptors, independent of VEGFR1 tyrosine kinase activity or neuropilin binding; this involves induction of ER stress via upregulation of BiP and ER stress sensors (ATF6, PERK, IRE1α), activating the unfolded protein response through XBP1.","method":"VEGFR1 TK-/- mice, VEGF-B186R127S NRP-binding mutant, adenoviral gene transfer in mouse hearts, in vitro cardiac endothelial cells, pig and wild-type mouse validation, integrin identification","journal":"Molecular therapy","confidence":"High","confidence_rationale":"Tier 1 / Moderate — multiple genetic models (TK-KO, NRP-binding mutant), receptor identification with mechanistic pathway, validated in multiple species; single lab","pmids":["40083161"],"is_preprint":false},{"year":2023,"finding":"VEGF-B binds to FGFR1, induces FGFR1/VEGFR1 complex formation, and suppresses FGF2-induced Erk activation, thereby inhibiting FGF2-driven angiogenesis and tumor growth when FGF2/FGFR1 levels are high; VEGF-B thus acts as an endogenous inhibitor of angiogenesis under these conditions.","method":"In vitro binding assay (VEGF-B to FGFR1), co-immunoprecipitation (FGFR1/VEGFR1 complex), Erk activation assay, in vivo angiogenesis and tumor models","journal":"Signal transduction and targeted therapy","confidence":"High","confidence_rationale":"Tier 2 / Strong — receptor binding, complex formation by Co-IP, downstream signaling assay, in vivo validation in one study","pmids":["37591843"],"is_preprint":false},{"year":2003,"finding":"Vegfb knockout mice show reduced synovial angiogenesis and reduced pathology (swelling, inflammation) in both antigen-induced and collagen-induced arthritis models, implicating VEGF-B in pathological vascular remodeling during inflammatory arthritis.","method":"Vegfb-/- mice in two arthritis models, histological scoring, synovial vessel density quantification","journal":"Arthritis and rheumatism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean KO in two disease models with defined vascular and inflammatory readouts, single lab","pmids":["13130487"],"is_preprint":false},{"year":2005,"finding":"VEGF-B stimulates neurogenesis in the adult brain; intracerebroventricular VEGF-B administration increased BrdU incorporation into cells of neuronal lineage in the hippocampal dentate gyrus and forebrain subventricular zone both in vitro and in vivo, and Vegfb-KO mice showed impaired neurogenesis.","method":"Vegfb-KO mice, intracerebroventricular injection, BrdU incorporation assay, neuronal marker immunostaining","journal":"Developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO plus gain-of-function rescue, defined neurogenesis readout; single lab","pmids":["16337622"],"is_preprint":false},{"year":2010,"finding":"RTEF-1 in endothelial cells directly increases VEGF-B promoter activity through a direct interaction (confirmed by ChIP and luciferase assay); endothelium-derived VEGF-B then stimulates hypertrophic gene expression in adjacent cardiomyocytes via ERK1/2, which was abrogated by VEGF-B siRNA.","method":"Chromatin immunoprecipitation, luciferase promoter assay, siRNA knockdown, cardiomyocyte conditioned medium experiments, VE-Cad/RTEF-1 transgenic mice","journal":"Cardiovascular research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct promoter interaction by ChIP/luciferase, paracrine mechanism by siRNA rescue; single lab","pmids":["21169295"],"is_preprint":false},{"year":2016,"finding":"VEGFB expression is found in cardiomyocytes with a postnatal ventricular shift, while VEGFR1 expression is restricted to endothelial cells in heart, lung, and kidney, supporting a tightly controlled paracrine signaling mechanism; reduced VEGFR1 expression resulted in decreased cardiac fatty acid accumulation and increased peripheral insulin sensitivity.","method":"β-galactosidase knock-in reporter mice, immunofluorescence microscopy, Flt1 heterozygous metabolic phenotyping","journal":"Cell and tissue research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reporter gene localization plus functional metabolic phenotype; single lab","pmids":["26928042"],"is_preprint":false},{"year":2017,"finding":"In the diabetic heart, surface-bound VEGFB on cardiomyocytes is released by endothelial heparanase secretion; high glucose and heparanase trigger VEGFB release, which then acts on endothelial cells (autocrine) and cardiomyocytes (paracrine) to promote survival via ERK signaling. Under hyperglycemia, VEGFB production is impaired and VEGFR1 expression is compensatorily increased.","method":"Diabetic heart models, heparanase secretion experiments, ERK signaling assays, gene expression analysis","journal":"American journal of physiology. Heart and circulatory physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — bidirectional signaling mechanism identified with cell/molecular assays; single lab, limited receptor-specific genetic tools used","pmids":["28314760"],"is_preprint":false},{"year":2017,"finding":"Exogenous VEGF-B promotes diabetic corneal nerve fiber regeneration through reactivation of PI3K/Akt-GSK3β-mTOR signaling and attenuation of neuronal mitochondrial dysfunction via VEGF receptor-1 and neuropilin-1; VEGF-B also elevated corneal pigment epithelial-derived factor (PEDF), and PEDF blockade partially abolished VEGF-B trophic effects.","method":"Type 1 diabetic mouse model, trigeminal ganglion cultures, VEGFR-1/NRP-1 pathway analysis, PEDF blocking antibody","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro and in vivo, two receptors identified, downstream signaling defined, partial receptor blockade validation; single lab","pmids":["28091556"],"is_preprint":false},{"year":2020,"finding":"VEGF-B promotes the formation of endocardium-derived coronary vessels during cardiac development; in adult mice, VEGF-B gene transfer induces endothelial proliferation predominantly in subendocardial coronary vessels and promotes endocardium-derived vessel development into myocardium after infarction.","method":"VEGF-B transgenic mice and rats, Vegfb-gene-deleted mice/rats, lineage tracing (apelin-CreERT, NPR3-CreERT), AAV gene transfer, histology, single-cell RNA-seq, microCT","journal":"Circulation","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic gain- and loss-of-function with lineage tracing and multiple orthogonal imaging/molecular methods; published in Circulation","pmids":["33203221"],"is_preprint":false},{"year":2021,"finding":"VEGFB promotes C2C12 myoblast proliferation and differentiation through VEGFR1-PI3K/Akt (and PI3K/Akt/mTOR for differentiation); VEGFR1 knockdown abolished VEGFB-stimulated proliferation and differentiation, and NRP1 knockdown did not affect differentiation.","method":"C2C12 myoblast cell line, VEGFR1/NRP1 siRNA knockdown, PI3K/Akt inhibitors, proliferation and differentiation assays","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — receptor-specific knockdown, pathway inhibitors, two functional readouts; single lab","pmids":["34948148"],"is_preprint":false},{"year":2020,"finding":"VEGF-B is expressed in Müller cells and acts as an autocrine gliotrophic factor under pathologic conditions (hypoxia, oxidative stress); VEGF-B neutralization under pathologic conditions enhanced Müller cell death and decreased Kir4.1 and aquaporin-4 expression, while recombinant VEGF-B restored glutamine synthetase and normalized TRPV4 channel expression and activity.","method":"Human and mouse Müller cell lines and primary cells, RT-PCR, ELISA, Western blot, VEGF-B neutralization, calcium imaging (Fura-2)","journal":"Investigative ophthalmology & visual science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — autocrine mechanism with neutralization and recombinant protein rescue, multiple functional readouts; single lab","pmids":["32945843"],"is_preprint":false},{"year":2016,"finding":"VEGF-B gene therapy prevented doxorubicin-induced cardiac atrophy, capillary rarefaction, and endothelial apoptosis; VEGF-B promoted coronary arteriogenesis and physiological cardiac hypertrophy, and protected cultured endothelial cells from apoptosis restoring tube formation.","method":"AAV gene therapy in tumor-bearing mice, endothelial cell culture, apoptosis assay, tube formation assay, cardiac function by echocardiography","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo gene therapy plus in vitro mechanistic validation with multiple readouts; single lab","pmids":["27799559"],"is_preprint":false},{"year":2017,"finding":"VEGFB-VEGFR1 signaling prevents Ang II-induced cardiomyocyte hypertrophy via Ca2+-mediated PKG I pathway; VEGFB reduced Ang II-induced Ca2+ elevation, prevented increases in β-MHC/BNP/ANP, and maintained PKG I/p-VASP/RGS2; VEGFR1 knockdown partially reversed these effects.","method":"H9C2 cardiomyocyte cell line, Ang II stimulation, VEGFR1 siRNA knockdown, Ca2+ measurement, PKG I/p-VASP/RGS2 Western blot","journal":"Journal of cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — receptor-specific knockdown, Ca2+ and PKG pathway established; single lab, cell line only","pmids":["28771828"],"is_preprint":false},{"year":2020,"finding":"High-dose VEGF-B overexpression in the heart induces sympathetic nerve sprouting (increased nerve density ~2-fold) via a VEGFR-1 signaling-independent mechanism, upregulating Nr4a2, ATF6, and MANF, and leading to increased risk of ventricular arrhythmias and sudden cardiac death.","method":"αMHC-VEGF-B transgenic mice, adenoviral VEGF-B186 pig cardiac gene transfer, immunostaining for nerve density, dobutamine stress testing, gene expression analysis, survival analysis","journal":"Molecular therapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — two species, transgenic and gene transfer models, VEGFR1-independence noted, nerve sprouting mechanism identified; single lab","pmids":["32243833"],"is_preprint":false},{"year":2024,"finding":"Autocrine VEGF-B signaling in activated T cells controls lipid synthesis and mitochondrial inner membrane integrity (cardiolipin maintenance) for T cell survival; disruption of VEGF-B signaling reduced cardiolipin mass, increased apoptosis, and reduced memory T cell development. Mechanistically, VEGF-B signaling through GABPα induces SENP2 expression, which de-SUMOylates PPARγ to enhance phospholipid synthesis.","method":"T cell-specific VEGF-B disruption, cardiolipin mass spectrometry, apoptosis assays, memory T cell flow cytometry, GABPα/SENP2/PPARγ molecular pathway analysis","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic disruption plus defined molecular pathway (GABPα→SENP2→deSUMOylation of PPARγ→cardiolipin), multiple orthogonal readouts; published in JCI","pmids":["39145452"],"is_preprint":false},{"year":2024,"finding":"VEGF-B prevents hyperglycemia-induced retinal vascular leakage by upregulating CDC42/ZO1/VE-cadherin expression; VEGF-B knockdown increased hyperglycemia-induced vascular leakage in human retinal endothelial cells, while VEGF-B overexpression or intravitreal injection restored CDC42/ZO1/VE-cadherin and reduced leakage.","method":"STZ-induced diabetic mouse model, VEGF-B knockdown/overexpression in HRECs, label-free proteomics, Western blot, whole-mount staining, intravitreal injection","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro and in vivo, defined pathway (CDC42-ZO1/VE-cadherin), proteomic discovery with validation; single lab","pmids":["39215561"],"is_preprint":false},{"year":2021,"finding":"Cardiac-specific VEGFB overexpression reduces lipoprotein lipase (LPL) activity at the coronary lumen through multiple regulatory mechanisms, lowers accumulation of lipid intermediates (diacylglycerols, lysophosphatidylcholine), and improves cardiac insulin sensitivity.","method":"Cardiomyocyte-specific VEGFB transgenic rats, RNA sequencing, Langendorff heart LPL activity assay, untargeted metabolomics, insulin sensitivity assay, high-resolution respirometry","journal":"American journal of physiology. Endocrinology and metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cardiac transgenic model with multi-omic readouts and direct LPL activity measurement; single lab","pmids":["34747201"],"is_preprint":false},{"year":1999,"finding":"VEGF-B is expressed predominantly in the developing myocardium (not endothelial cells), while its receptor VEGFR-1 is almost exclusively present in endothelial cells, supporting a paracrine mode of action in vascular development.","method":"In situ hybridization and immunohistochemistry in mouse embryos (E8.5–E17.5)","journal":"Developmental dynamics","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — direct localization by two independent methods across developmental stages; functional paracrine inference from localization data","pmids":["10340753"],"is_preprint":false}],"current_model":"VEGF-B is a secreted disulfide-linked homodimer (with two alternative isoforms, VEGF-B167 and VEGF-B186) that signals primarily through VEGFR1/Flt-1 (and neuropilin-1), and has been mechanistically established to: (1) regulate endothelial fatty acid uptake/transport by controlling lipid transporter expression and LDLR recycling/membrane cholesterol, thereby controlling tissue lipid accumulation and contributing to metabolic disease; (2) promote cell survival and inhibit apoptosis by suppressing BH3-only protein gene expression downstream of VEGFR1, protecting vascular cells, neurons, and cardiomyocytes; (3) upregulate antioxidant defenses (particularly Gpx1) via VEGFR1; (4) activate VEGFR1 on cardiomyocytes to induce compensatory hypertrophy, arteriogenesis, and endocardium-derived coronary vessel formation; (5) promote cardiac angiogenesis through RGD-binding integrins (ITGAV/ITGA5) and ER stress/UPR independently of VEGFR1 kinase activity; (6) bind FGFR1, induce FGFR1/VEGFR1 complexes, and suppress FGF2-driven angiogenesis when FGF2/FGFR1 levels are high; (7) support T cell survival through autocrine signaling via GABPα/SENP2/PPARγ-mediated cardiolipin synthesis; and (8) regulate vascular integrity in the retina through the CDC42-ZO1/VE-cadherin pathway, while being dispensable for developmental blood vessel growth but critical for vascular cell survival."},"narrative":{"mechanistic_narrative":"VEGF-B is a secreted disulfide-linked homodimer that exists as two alternatively spliced isoforms (VEGF-B167 and VEGF-B186), the latter O-glycosylated post-secretion and capable of forming heterodimers with VEGF-A [PMID:8702615]. Unlike VEGF-A, its expression is not induced by hypoxia, Ras, or mutant p53 and its mRNA is unusually stable, marking it as a constitutive rather than stress-inducible angiogenic factor [PMID:9188862]. It signals chiefly by binding VEGFR-1/Flt-1 and neuropilin-1 in a paracrine arrangement, where ligand is produced by myocardium while receptor is restricted to endothelium [PMID:9751730, PMID:10340753, PMID:19369214]. Two dominant functional themes emerge. First, VEGF-B is a survival and cytoprotective factor: through VEGFR-1 it suppresses pro-apoptotic BH3-only genes and other death-related genes to protect endothelial cells, pericytes, neurons, and cardiomyocytes [PMID:18259607, PMID:19369214], protects motor and sensory neurons via neuronal Flt-1 tyrosine kinase activity and mitochondrial maintenance [PMID:18923022, PMID:21248239], and upregulates antioxidant defenses—particularly Gpx1—to rescue degenerating retina [PMID:30249667]. Second, VEGF-B is a central regulator of tissue lipid handling and metabolism: it controls endothelial fatty acid uptake/transport such that its inhibition prevents ectopic lipid deposition and restores insulin sensitivity in diabetic models [PMID:27076080], is transcriptionally driven by PGC-1α/ERR-α in muscle [PMID:26822083], impairs LDLR recycling to lower membrane cholesterol and GLUT1-dependent glucose uptake [PMID:32449307], and modulates adipose lipolysis through hormone-sensitive lipase to influence NAFLD [PMID:36717026]. In the heart, VEGF-B activates VEGFR-1 on cardiomyocytes to drive compensatory hypertrophy, arteriogenesis, and endocardium-derived coronary vessel formation [PMID:20019242, PMID:33203221], while VEGF-B186 can also promote cardiac angiogenesis through RGD-binding integrins (ITGAV/ITGA5) and ER-stress/UPR signaling independently of VEGFR-1 kinase activity [PMID:40083161]. VEGF-B additionally engages FGFR1, inducing FGFR1/VEGFR1 complexes that suppress FGF2-driven angiogenesis under high FGF2/FGFR1 conditions, positioning it as a context-dependent endogenous angiogenesis inhibitor [PMID:37591843]. VEGF-B is dispensable for developmental blood vessel growth but is required for vascular cell survival and integrity [PMID:19369214, PMID:39215561].","teleology":[{"year":1996,"claim":"Established the molecular identity and biochemistry of VEGF-B, defining isoforms, dimerization, and heterodimer potential with VEGF-A — the structural foundation for all downstream signaling work.","evidence":"cDNA cloning, transfection, SDS-PAGE and glycosylation analysis of VEGF-B186","pmids":["8702615"],"confidence":"High","gaps":["Receptor and downstream signaling not yet defined","Functional difference between isoforms unresolved"]},{"year":1998,"claim":"Identified VEGFR-1/Flt-1 as the receptor and showed receptor engagement drives a pro-fibrinolytic endothelial program, while a separate study established that VEGF-B regulation is fundamentally distinct from the hypoxia-driven VEGF-A.","evidence":"Receptor binding assay with site-directed mutagenesis plus endothelial functional readout; Northern blot and mRNA stability assays","pmids":["9751730","9188862"],"confidence":"High","gaps":["In vivo physiological role not established","Downstream signaling cascade beyond uPA/PAI-1 unknown"]},{"year":1999,"claim":"Defined the paracrine architecture: ligand in myocardium, receptor in endothelium, framing VEGF-B as a cardiac-vascular paracrine signal.","evidence":"In situ hybridization and immunohistochemistry across mouse embryonic stages","pmids":["10340753"],"confidence":"Medium","gaps":["Paracrine function inferred from localization, not functionally tested here","Adult expression pattern not addressed"]},{"year":2000,"claim":"First loss-of-function evidence linked VEGF-B to coronary vasculature and recovery from cardiac ischemia, moving it from biochemistry to physiology.","evidence":"Vegfb knockout mice with cardiac phenotyping and coronary occlusion model","pmids":["10666423"],"confidence":"High","gaps":["Cellular mechanism (survival vs growth) unresolved","Receptor-dependence in vivo not dissected"]},{"year":2003,"claim":"Extended VEGF-B to pathological vascular remodeling, showing it drives synovial angiogenesis and inflammation in arthritis.","evidence":"Vegfb-/- mice in antigen- and collagen-induced arthritis with histological and vessel-density scoring","pmids":["13130487"],"confidence":"Medium","gaps":["Mechanism of synovial angiogenesis not defined","Receptor and cell-type specificity unknown"]},{"year":2008,"claim":"Defined the core cytoprotective mechanism — VEGFR-1-dependent suppression of BH3-only pro-apoptotic genes — and demonstrated neuroprotection in vivo, recasting VEGF-B as a survival factor rather than a growth factor.","evidence":"Gene expression profiling, qPCR, and in vivo retinal/stroke neuroprotection models","pmids":["18259607"],"confidence":"High","gaps":["Signaling intermediates from VEGFR-1 to gene suppression not mapped","Cell-type generality not yet tested"]},{"year":2009,"claim":"Established that VEGF-B is dispensable for vessel growth but essential for vascular cell survival via NRP-1 and VEGFR-1, and that VEGF-B186 protects motor neurons through neuronal Flt-1 tyrosine kinase activity.","evidence":"Multiple vascular cell assays and animal models; primary motor neuron cultures, Vegfb/SOD1 double mutants, ICV delivery, kinase inhibitors","pmids":["19369214","18923022"],"confidence":"High","gaps":["Relative contributions of NRP-1 vs VEGFR-1 not quantified","Downstream survival effectors in neurons not fully defined"]},{"year":2009,"claim":"Showed VEGF-B186 directly acts on cardiomyocytes through VEGFR-1 to elicit antiapoptotic and compensatory hypertrophic transcriptional programs preserving post-infarct cardiac function.","evidence":"AAV gene delivery in rats, cardiomyocyte culture, gene expression profiling, MI model","pmids":["20019242"],"confidence":"High","gaps":["Long-term safety of induced hypertrophy not assessed","Endothelial vs cardiomyocyte contributions not separated"]},{"year":2011,"claim":"Demonstrated direct neuronal action on sensory neurons via FLT1 with mitochondrial membrane potential maintenance, distinguishing neuronal from vascular protection.","evidence":"DRG cultures from Vegfb/Flt1 KO mice, paclitaxel neuropathy model, neuronal FLT1 transgenics, recombinant protein","pmids":["21248239"],"confidence":"High","gaps":["Mechanism coupling FLT1 to mitochondrial integrity unresolved","Translation to human neuropathy untested"]},{"year":2010,"claim":"Established VEGF-B as a master regulator of endothelial fatty acid uptake, linking it to ectopic lipid deposition, insulin resistance, and metabolic disease — a major functional pivot.","evidence":"Vegfb knockout in db/db mice and antibody inhibition in HFD rats with metabolic readouts","pmids":["23023133"],"confidence":"High","gaps":["Identity of regulated lipid transporters not fully defined here","Tissue-specific versus systemic effects unresolved"]},{"year":2016,"claim":"Mapped upstream transcriptional control (PGC-1α/ERR-α) of Vegfb in muscle and showed VEGFB-VEGFR1 signaling activates VEGF/VEGFR2-dependent angiogenesis to improve adipose perfusion and insulin supply, while reporter studies confirmed the cardiomyocyte-to-endothelium paracrine axis.","evidence":"PGC-1α transgenic and Vegfb KO crosses; Vegfb gene transduction with endothelial Flt1 cKO; β-gal knock-in reporter mice and Flt1 heterozygote phenotyping","pmids":["26822083","27076080","26928042"],"confidence":"High","gaps":["Reconciliation of VEGFB as both lipid-uptake promoter and perfusion enhancer not fully integrated","Crosstalk to VEGFR2 mechanism not molecularly resolved"]},{"year":2017,"claim":"Extended the metabolic role to diabetic kidney disease, showing VEGF-B inhibition reduces renal lipotoxicity and restores podocyte insulin signaling, with parallel work defining diabetic-heart heparanase-triggered VEGFB release and PEDF-dependent corneal nerve regeneration.","evidence":"DKD mouse models with anti-VEGF-B antibody; diabetic heart heparanase secretion and ERK assays; diabetic corneal nerve model with VEGFR-1/NRP-1 and PEDF blockade","pmids":["28190774","28314760","28091556"],"confidence":"Medium","gaps":["Receptor-specific genetic dissection limited in heparanase study","Whether renal and cardiac effects share a common transporter mechanism unknown"]},{"year":2018,"claim":"Identified VEGF-B as a potent antioxidant acting mainly through VEGFR-1 and Gpx1, providing a redox-based arm of its cytoprotection in the retina.","evidence":"Vegfb and Gpx1 KO mice with epistasis, retinitis pigmentosa model, expression profiling","pmids":["30249667"],"confidence":"High","gaps":["Signaling linking VEGFR-1 to antioxidant gene induction not mapped","Generality beyond retina untested"]},{"year":2020,"claim":"Resolved a key metabolic mechanism — VEGF-B impairs LDLR recycling to reduce membrane cholesterol and GLUT1-dependent glucose uptake — and demonstrated VEGF-B drives endocardium-derived coronary vessel formation, while autocrine VEGF-B sustains Müller glia and high-dose cardiac VEGF-B triggers VEGFR-1-independent sympathetic nerve sprouting with arrhythmia risk.","evidence":"Endothelial LDLR trafficking and cholesterol/GLUT1 assays with in vivo inhibition; lineage tracing and scRNA-seq in VEGF-B transgenic/KO hearts; Müller cell neutralization/rescue; αMHC-VEGF-B transgenic and pig gene transfer","pmids":["32449307","33203221","32945843","32243833"],"confidence":"High","gaps":["Receptor identity for nerve-sprouting and gliotrophic effects not fully defined","Dose threshold for beneficial vs arrhythmogenic cardiac effects unclear"]},{"year":2021,"claim":"Defined VEGFB-VEGFR1-PI3K/Akt control of myoblast proliferation/differentiation and cardiomyocyte-specific metabolic and anti-hypertrophic effects, including reduced coronary LPL activity and protection against Ang II hypertrophy via Ca2+/PKG I.","evidence":"C2C12 receptor knockdown and pathway inhibitors; cardiac transgenic rats with multi-omics and LPL activity; H9C2 Ang II model with VEGFR1 knockdown and PKG pathway analysis","pmids":["34948148","34747201","28771828"],"confidence":"Medium","gaps":["Cell-line-based findings need in vivo confirmation","Integration of metabolic and anti-hypertrophic effects mechanistically incomplete"]},{"year":2023,"claim":"Uncovered context-dependent angiogenesis inhibition via FGFR1 binding and FGFR1/VEGFR1 complex formation suppressing FGF2/Erk signaling, and defined an adipose lipolysis mechanism (HSL) by which VEGF-B influences NAFLD.","evidence":"In vitro binding, Co-IP, Erk assays and in vivo tumor/angiogenesis models; adipocyte-specific VEGF-B transgenic/KO mice with lipolysis and HSL assays","pmids":["37591843","36717026"],"confidence":"High","gaps":["Structural basis of FGFR1/VEGFR1 complex unresolved","How VEGF-B switches between pro- and anti-angiogenic roles in vivo unclear"]},{"year":2024,"claim":"Revealed an autocrine immunometabolic role: VEGF-B sustains T cell survival and memory via a GABPα→SENP2→PPARγ deSUMOylation axis driving cardiolipin synthesis, and a retinal vascular-integrity role via the CDC42/ZO1/VE-cadherin pathway.","evidence":"T cell-specific VEGF-B disruption with cardiolipin mass spec and GABPα/SENP2/PPARγ analysis; STZ diabetic mice and HREC knockdown/overexpression with proteomics","pmids":["39145452","39215561"],"confidence":"High","gaps":["Receptor mediating T cell autocrine signaling not specified","Link between barrier integrity pathway and canonical VEGFR-1 signaling unresolved"]},{"year":2025,"claim":"Identified RGD-binding integrins ITGAV and ITGA5 as new VEGF-B186 receptors mediating cardiac angiogenesis through ER stress/UPR, independent of VEGFR-1 kinase activity, expanding the receptor repertoire beyond Flt-1.","evidence":"VEGFR1 TK-KO mice, NRP-binding mutant, adenoviral cardiac gene transfer, cardiac endothelial cells, multi-species validation, integrin identification","pmids":["40083161"],"confidence":"High","gaps":["Relative in vivo contribution of integrin vs VEGFR-1 pathways not quantified","Structural basis of integrin engagement unresolved"]},{"year":null,"claim":"How VEGF-B integrates its multiple receptors (VEGFR-1, NRP-1, FGFR1, RGD-integrins) into context-specific outputs — survival, lipid handling, angiogenesis promotion vs inhibition — remains unresolved at the level of a unified signaling logic.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model of VEGF-B with its non-Flt1 receptors","Determinants selecting between pro- and anti-angiogenic outcomes unknown","Receptor usage in immune and metabolic contexts not fully mapped"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[0,5,7,16,17]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[4,13,17]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[2,0]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,7,25,28]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[10,11,14,15,32]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[4,5]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[13,16]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[3,24,33]}],"complexes":["FGFR1/VEGFR1 complex"],"partners":["FLT1","NRP1","FGFR1","ITGAV","ITGA5","VEGFA"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P49765","full_name":"Vascular endothelial growth factor B","aliases":["VEGF-related factor","VRF"],"length_aa":207,"mass_kda":21.6,"function":"Growth factor for endothelial cells. VEGF-B167 binds heparin and neuropilin-1 whereas the binding to neuropilin-1 of VEGF-B186 is regulated by proteolysis","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P49765/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/VEGFB","classification":"Not Classified","n_dependent_lines":10,"n_total_lines":1208,"dependency_fraction":0.008278145695364239},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/VEGFB","total_profiled":1310},"omim":[{"mim_id":"604189","title":"DNAJ/HSP40 HOMOLOG, SUBFAMILY C, MEMBER 4; DNAJC4","url":"https://www.omim.org/entry/604189"},{"mim_id":"601528","title":"VASCULAR ENDOTHELIAL GROWTH FACTOR C; VEGFC","url":"https://www.omim.org/entry/601528"},{"mim_id":"601398","title":"VASCULAR ENDOTHELIAL GROWTH FACTOR B; VEGFB","url":"https://www.omim.org/entry/601398"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/VEGFB"},"hgnc":{"alias_symbol":["VEGFL"],"prev_symbol":["VRF"]},"alphafold":{"accession":"P49765","domains":[{"cath_id":"2.10.90.10","chopping":"50-128","consensus_level":"medium","plddt":91.9496,"start":50,"end":128}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P49765","model_url":"https://alphafold.ebi.ac.uk/files/AF-P49765-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P49765-F1-predicted_aligned_error_v6.png","plddt_mean":73.5},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=VEGFB","jax_strain_url":"https://www.jax.org/strain/search?query=VEGFB"},"sequence":{"accession":"P49765","fasta_url":"https://rest.uniprot.org/uniprotkb/P49765.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P49765/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P49765"}},"corpus_meta":[{"pmid":"9751730","id":"PMC_9751730","title":"Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells.","date":"1998","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9751730","citation_count":441,"is_preprint":false},{"pmid":"9188862","id":"PMC_9188862","title":"Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia.","date":"1997","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/9188862","citation_count":389,"is_preprint":false},{"pmid":"9665470","id":"PMC_9665470","title":"Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors.","date":"1998","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/9665470","citation_count":285,"is_preprint":false},{"pmid":"23023133","id":"PMC_23023133","title":"Targeting VEGF-B as a novel treatment for insulin resistance and type 2 diabetes.","date":"2012","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/23023133","citation_count":244,"is_preprint":false},{"pmid":"19369214","id":"PMC_19369214","title":"VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis.","date":"2009","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/19369214","citation_count":243,"is_preprint":false},{"pmid":"10666423","id":"PMC_10666423","title":"Mice lacking the vascular endothelial growth factor-B gene (Vegfb) have smaller hearts, dysfunctional coronary vasculature, and impaired recovery from cardiac ischemia.","date":"2000","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/10666423","citation_count":232,"is_preprint":false},{"pmid":"27076080","id":"PMC_27076080","title":"VEGFB/VEGFR1-Induced Expansion of Adipose Vasculature Counteracts Obesity and Related Metabolic Complications.","date":"2016","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/27076080","citation_count":192,"is_preprint":false},{"pmid":"12754739","id":"PMC_12754739","title":"The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression.","date":"2003","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/12754739","citation_count":186,"is_preprint":false},{"pmid":"8702615","id":"PMC_8702615","title":"Genomic organization of the mouse and human genes for vascular endothelial growth factor B (VEGF-B) and characterization of a second splice isoform.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8702615","citation_count":169,"is_preprint":false},{"pmid":"18259607","id":"PMC_18259607","title":"VEGF-B inhibits apoptosis via VEGFR-1-mediated suppression of the expression of BH3-only protein genes in mice and rats.","date":"2008","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/18259607","citation_count":168,"is_preprint":false},{"pmid":"9834463","id":"PMC_9834463","title":"Comparison of expression patterns for placenta growth factor, vascular endothelial growth factor (VEGF), VEGF-B and VEGF-C in the human placenta throughout gestation.","date":"1998","source":"The Journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/9834463","citation_count":162,"is_preprint":false},{"pmid":"28190774","id":"PMC_28190774","title":"Reducing VEGF-B Signaling Ameliorates Renal Lipotoxicity and Protects against Diabetic Kidney Disease.","date":"2017","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/28190774","citation_count":158,"is_preprint":false},{"pmid":"20019242","id":"PMC_20019242","title":"Cardiomyocyte VEGFR-1 activation by VEGF-B induces compensatory hypertrophy and preserves cardiac function after myocardial infarction.","date":"2009","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/20019242","citation_count":152,"is_preprint":false},{"pmid":"16337622","id":"PMC_16337622","title":"Vascular endothelial growth factor-B (VEGFB) stimulates neurogenesis: evidence from knockout mice and growth factor administration.","date":"2005","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/16337622","citation_count":147,"is_preprint":false},{"pmid":"10600689","id":"PMC_10600689","title":"Current biology of VEGF-B and VEGF-C.","date":"1999","source":"Current opinion in biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/10600689","citation_count":133,"is_preprint":false},{"pmid":"10738243","id":"PMC_10738243","title":"Vegf, Vegf-B, Vegf-C and their receptors KDR, FLT-1 and FLT-4 during the neoplastic progression of human colonic mucosa.","date":"2000","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/10738243","citation_count":124,"is_preprint":false},{"pmid":"18923022","id":"PMC_18923022","title":"Novel role for vascular endothelial growth factor (VEGF) receptor-1 and its ligand VEGF-B in motor neuron degeneration.","date":"2008","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/18923022","citation_count":118,"is_preprint":false},{"pmid":"27799559","id":"PMC_27799559","title":"VEGF-B gene therapy inhibits doxorubicin-induced cardiotoxicity by endothelial protection.","date":"2016","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/27799559","citation_count":113,"is_preprint":false},{"pmid":"35028009","id":"PMC_35028009","title":"Resveratrol Treats UVB-Induced Photoaging by Anti-MMP Expression, through Anti-Inflammatory, Antioxidant, and Antiapoptotic Properties, and Treats Photoaging by Upregulating VEGF-B Expression.","date":"2022","source":"Oxidative medicine and cellular longevity","url":"https://pubmed.ncbi.nlm.nih.gov/35028009","citation_count":109,"is_preprint":false},{"pmid":"9348202","id":"PMC_9348202","title":"Differential hormonal regulation of vascular endothelial growth factors VEGF, VEGF-B, and VEGF-C messenger ribonucleic acid levels in cultured human granulosa-luteal cells.","date":"1997","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/9348202","citation_count":108,"is_preprint":false},{"pmid":"13130487","id":"PMC_13130487","title":"Vegfb gene knockout mice display reduced pathology and synovial angiogenesis in both antigen-induced and collagen-induced models of arthritis.","date":"2003","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/13130487","citation_count":106,"is_preprint":false},{"pmid":"11312110","id":"PMC_11312110","title":"Novel VEGF family members: VEGF-B, VEGF-C and VEGF-D.","date":"2001","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/11312110","citation_count":102,"is_preprint":false},{"pmid":"19684473","id":"PMC_19684473","title":"VEGF-B: a survival, or an angiogenic factor?","date":"2009","source":"Cell adhesion & migration","url":"https://pubmed.ncbi.nlm.nih.gov/19684473","citation_count":88,"is_preprint":false},{"pmid":"33203221","id":"PMC_33203221","title":"VEGF-B Promotes Endocardium-Derived Coronary Vessel Development and Cardiac Regeneration.","date":"2020","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/33203221","citation_count":86,"is_preprint":false},{"pmid":"8653826","id":"PMC_8653826","title":"Novel human vascular endothelial growth factor genes VEGF-B and VEGF-C localize to chromosomes 11q13 and 4q34, respectively.","date":"1996","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/8653826","citation_count":82,"is_preprint":false},{"pmid":"10340753","id":"PMC_10340753","title":"Localization of VEGF-B in the mouse embryo suggests a paracrine role of the growth factor in the developing vasculature.","date":"1999","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/10340753","citation_count":77,"is_preprint":false},{"pmid":"16286239","id":"PMC_16286239","title":"The biology of vascular endothelial growth factor-B (VEGF-B).","date":"2005","source":"Pulmonary pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/16286239","citation_count":75,"is_preprint":false},{"pmid":"12230324","id":"PMC_12230324","title":"Differential expression of vascular endothelial growth factor-A (VEGF-A) and VEGF-B after brain injury.","date":"2002","source":"Journal of neuropathology and experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/12230324","citation_count":70,"is_preprint":false},{"pmid":"11678209","id":"PMC_11678209","title":"Isoform-specific expression of VEGF-B in normal tissues and tumors.","date":"2001","source":"Growth factors (Chur, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/11678209","citation_count":69,"is_preprint":false},{"pmid":"9689915","id":"PMC_9689915","title":"A comparative study of the expression patterns for vegf, vegf-b/vrf and vegf-c in the developing and adult mouse.","date":"1998","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/9689915","citation_count":68,"is_preprint":false},{"pmid":"23089731","id":"PMC_23089731","title":"AAV9-mediated VEGF-B gene transfer improves systolic function in progressive left ventricular hypertrophy.","date":"2012","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/23089731","citation_count":67,"is_preprint":false},{"pmid":"20303947","id":"PMC_20303947","title":"Heme oxygenase-1 and carbon monoxide promote neovascularization after myocardial infarction by modulating the expression of HIF-1alpha, SDF-1alpha and VEGF-B.","date":"2010","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/20303947","citation_count":64,"is_preprint":false},{"pmid":"20003314","id":"PMC_20003314","title":"Vascular endothelial growth factor B (VEGF-B) is up-regulated and exogenous VEGF-B is neuroprotective in a culture model of Parkinson's disease.","date":"2009","source":"Molecular neurodegeneration","url":"https://pubmed.ncbi.nlm.nih.gov/20003314","citation_count":58,"is_preprint":false},{"pmid":"30560942","id":"PMC_30560942","title":"A peptide mimicking the binding sites of VEGF-A and VEGF-B inhibits VEGFR-1/-2 driven angiogenesis, tumor growth and metastasis.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/30560942","citation_count":56,"is_preprint":false},{"pmid":"37591843","id":"PMC_37591843","title":"VEGF-B prevents excessive angiogenesis by inhibiting FGF2/FGFR1 pathway.","date":"2023","source":"Signal transduction and targeted therapy","url":"https://pubmed.ncbi.nlm.nih.gov/37591843","citation_count":55,"is_preprint":false},{"pmid":"33532185","id":"PMC_33532185","title":"VEGF-B antibody and interleukin-22 fusion protein ameliorates diabetic nephropathy through inhibiting lipid accumulation and inflammatory responses.","date":"2020","source":"Acta pharmaceutica Sinica. B","url":"https://pubmed.ncbi.nlm.nih.gov/33532185","citation_count":54,"is_preprint":false},{"pmid":"18317782","id":"PMC_18317782","title":"Cellular distribution of vascular endothelial growth factor A (VEGFA) and B (VEGFB) and VEGF receptors 1 and 2 in focal cortical dysplasia type IIB.","date":"2008","source":"Acta neuropathologica","url":"https://pubmed.ncbi.nlm.nih.gov/18317782","citation_count":53,"is_preprint":false},{"pmid":"30249667","id":"PMC_30249667","title":"VEGF-B is a potent antioxidant.","date":"2018","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/30249667","citation_count":52,"is_preprint":false},{"pmid":"26822083","id":"PMC_26822083","title":"PGC-1α Coordinates Mitochondrial Respiratory Capacity and Muscular Fatty Acid Uptake via Regulation of VEGF-B.","date":"2016","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/26822083","citation_count":52,"is_preprint":false},{"pmid":"15009103","id":"PMC_15009103","title":"Comparative expression of vascular endothelial growth factor family members, VEGF-B, -C and -D, by normal human keratinocytes and fibroblasts.","date":"2004","source":"Experimental dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/15009103","citation_count":51,"is_preprint":false},{"pmid":"24291725","id":"PMC_24291725","title":"Comparative study of the neurotrophic effects elicited by VEGF-B and GDNF in preclinical in vivo models of Parkinson's disease.","date":"2013","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/24291725","citation_count":51,"is_preprint":false},{"pmid":"11241411","id":"PMC_11241411","title":"VEGF-B expression in human primary breast cancers is associated with lymph node metastasis but not angiogenesis.","date":"2001","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/11241411","citation_count":49,"is_preprint":false},{"pmid":"21248239","id":"PMC_21248239","title":"Neuronal FLT1 receptor and its selective ligand VEGF-B protect against retrograde degeneration of sensory neurons.","date":"2011","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/21248239","citation_count":48,"is_preprint":false},{"pmid":"12547729","id":"PMC_12547729","title":"Role of VEGF-B in the lung during development of chronic hypoxic pulmonary hypertension.","date":"2003","source":"American journal of physiology. Lung cellular and molecular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/12547729","citation_count":48,"is_preprint":false},{"pmid":"28091556","id":"PMC_28091556","title":"VEGF-B promotes recovery of corneal innervations and trophic functions in diabetic mice.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28091556","citation_count":46,"is_preprint":false},{"pmid":"36717026","id":"PMC_36717026","title":"Inhibition of VEGF-B signaling prevents non-alcoholic fatty liver disease development by targeting lipolysis in the white adipose tissue.","date":"2023","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/36717026","citation_count":45,"is_preprint":false},{"pmid":"34948148","id":"PMC_34948148","title":"VEGFB Promotes Myoblasts Proliferation and Differentiation through VEGFR1-PI3K/Akt Signaling Pathway.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34948148","citation_count":44,"is_preprint":false},{"pmid":"26928042","id":"PMC_26928042","title":"Expression of vascular endothelial growth factor (VEGF)-B and its receptor (VEGFR1) in murine heart, lung and kidney.","date":"2016","source":"Cell and tissue research","url":"https://pubmed.ncbi.nlm.nih.gov/26928042","citation_count":37,"is_preprint":false},{"pmid":"32449307","id":"PMC_32449307","title":"VEGF-B signaling impairs endothelial glucose transcytosis by decreasing membrane cholesterol content.","date":"2020","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/32449307","citation_count":36,"is_preprint":false},{"pmid":"30016789","id":"PMC_30016789","title":"VEGF-A and VEGF-B Coordinate the Arteriogenesis to Repair the Infarcted Heart with Vagus Nerve Stimulation.","date":"2018","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30016789","citation_count":36,"is_preprint":false},{"pmid":"25168313","id":"PMC_25168313","title":"Lack of cardiac and high-fat diet induced metabolic phenotypes in two independent strains of Vegf-b knockout mice.","date":"2014","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/25168313","citation_count":36,"is_preprint":false},{"pmid":"30851357","id":"PMC_30851357","title":"Novel function of VEGF-B as an antioxidant and therapeutic implications.","date":"2019","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/30851357","citation_count":35,"is_preprint":false},{"pmid":"28473940","id":"PMC_28473940","title":"Insights into the Mechanisms Involved in Protective Effects of VEGF-B in Dopaminergic Neurons.","date":"2017","source":"Parkinson's disease","url":"https://pubmed.ncbi.nlm.nih.gov/28473940","citation_count":35,"is_preprint":false},{"pmid":"16189273","id":"PMC_16189273","title":"Redundant roles of VEGF-B and PlGF during selective VEGF-A blockade in mice.","date":"2005","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/16189273","citation_count":33,"is_preprint":false},{"pmid":"27705937","id":"PMC_27705937","title":"Metformin potentiates anti-tumor effect of resveratrol on pancreatic cancer by down-regulation of VEGF-B signaling pathway.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27705937","citation_count":31,"is_preprint":false},{"pmid":"27146579","id":"PMC_27146579","title":"Dual effects of VEGF-B on activating cardiomyocytes and cardiac stem cells to protect the heart against short- and long-term ischemia-reperfusion injury.","date":"2016","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27146579","citation_count":30,"is_preprint":false},{"pmid":"35907871","id":"PMC_35907871","title":"Reducing VEGFB accelerates NAFLD and insulin resistance in mice via inhibiting AMPK signaling pathway.","date":"2022","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35907871","citation_count":29,"is_preprint":false},{"pmid":"30700502","id":"PMC_30700502","title":"A cyclic peptide reproducing the α1 helix of VEGF-B binds to VEGFR-1 and VEGFR-2 and inhibits angiogenesis and tumor growth.","date":"2019","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/30700502","citation_count":29,"is_preprint":false},{"pmid":"32243833","id":"PMC_32243833","title":"Susceptibility to Cardiac Arrhythmias and Sympathetic Nerve Growth in VEGF-B Overexpressing Myocardium.","date":"2020","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/32243833","citation_count":29,"is_preprint":false},{"pmid":"28314760","id":"PMC_28314760","title":"Loss of VEGFB and its signaling in the diabetic heart is associated with increased cell death signaling.","date":"2017","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/28314760","citation_count":28,"is_preprint":false},{"pmid":"19424629","id":"PMC_19424629","title":"Expression analysis of VEGF-A and VEGF-B: relationship with clinicopathological parameters in bladder cancer.","date":"2009","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/19424629","citation_count":28,"is_preprint":false},{"pmid":"31969592","id":"PMC_31969592","title":"VEGF-B ablation in pancreatic β-cells upregulates insulin expression without affecting glucose homeostasis or islet lipid uptake.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31969592","citation_count":25,"is_preprint":false},{"pmid":"37375853","id":"PMC_37375853","title":"A VEGFB-Based Peptidomimetic Inhibits VEGFR2-Mediated PI3K/Akt/mTOR and PLCγ/ERK Signaling and Elicits Apoptotic, Antiangiogenic, and Antitumor Activities.","date":"2023","source":"Pharmaceuticals (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/37375853","citation_count":24,"is_preprint":false},{"pmid":"36646672","id":"PMC_36646672","title":"Simultaneous blockade of VEGF-B and IL-17A ameliorated diabetic kidney disease by reducing ectopic lipid deposition and alleviating inflammation response.","date":"2023","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/36646672","citation_count":24,"is_preprint":false},{"pmid":"25001655","id":"PMC_25001655","title":"Clinical association of circulating VEGF-B levels with hyperlipidemia and target organ damage in type 2 diabetic patients.","date":"2014","source":"Journal of biological regulators and homeostatic agents","url":"https://pubmed.ncbi.nlm.nih.gov/25001655","citation_count":24,"is_preprint":false},{"pmid":"27189805","id":"PMC_27189805","title":"VEGF-B inhibits hyperglycemia- and Macugen-induced retinal apoptosis.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27189805","citation_count":22,"is_preprint":false},{"pmid":"39468621","id":"PMC_39468621","title":"VEGFB ameliorates insulin resistance in NAFLD via the PI3K/AKT signal pathway.","date":"2024","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39468621","citation_count":21,"is_preprint":false},{"pmid":"12366398","id":"PMC_12366398","title":"Effects of vascular endothelial growth factor (VEGF)A and VEGFB gene transfer on vascular reserve in a conscious rabbit hindlimb ischaemia model.","date":"2002","source":"Clinical and experimental pharmacology & physiology","url":"https://pubmed.ncbi.nlm.nih.gov/12366398","citation_count":18,"is_preprint":false},{"pmid":"36552897","id":"PMC_36552897","title":"Therapeutic Potential of VEGF-B in Coronary Heart Disease and Heart Failure: Dream or Vision?","date":"2022","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/36552897","citation_count":17,"is_preprint":false},{"pmid":"32054075","id":"PMC_32054075","title":"Oxidative Stress in Canine Histiocytic Sarcoma Cells Induced by an Infection with Canine Distemper Virus Led to a Dysregulation of HIF-1α Downstream Pathway Resulting in a Reduced Expression of VEGF-B in vitro.","date":"2020","source":"Viruses","url":"https://pubmed.ncbi.nlm.nih.gov/32054075","citation_count":17,"is_preprint":false},{"pmid":"35894135","id":"PMC_35894135","title":"Reducing VEGFB expression regulates the balance of glucose and lipid metabolism in mice via VEGFR1.","date":"2022","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/35894135","citation_count":16,"is_preprint":false},{"pmid":"39145452","id":"PMC_39145452","title":"Autocrine VEGF-B signaling maintains lipid synthesis and mitochondrial fitness to support T cell immune responses.","date":"2024","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/39145452","citation_count":16,"is_preprint":false},{"pmid":"35886871","id":"PMC_35886871","title":"Knockdown of VEGFB/VEGFR1 Signaling Promotes White Adipose Tissue Browning and Skeletal Muscle Development.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35886871","citation_count":15,"is_preprint":false},{"pmid":"34747201","id":"PMC_34747201","title":"Cardiac-specific VEGFB overexpression reduces lipoprotein lipase activity and improves insulin action in rat heart.","date":"2021","source":"American journal of physiology. Endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/34747201","citation_count":15,"is_preprint":false},{"pmid":"21169295","id":"PMC_21169295","title":"The endothelium-dependent effect of RTEF-1 in pressure overload cardiac hypertrophy: role of VEGF-B.","date":"2010","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/21169295","citation_count":15,"is_preprint":false},{"pmid":"29099033","id":"PMC_29099033","title":"VEGF-B Levels in the Vitreous of Diabetic and Non-Diabetic Patients with Ocular Diseases and Its Correlation with Structural Parameters.","date":"2017","source":"Medical sciences (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/29099033","citation_count":15,"is_preprint":false},{"pmid":"36582287","id":"PMC_36582287","title":"Optimized riboswitch-regulated AAV vector for VEGF-B gene therapy.","date":"2022","source":"Frontiers in medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36582287","citation_count":13,"is_preprint":false},{"pmid":"32945843","id":"PMC_32945843","title":"VEGF-B Is an Autocrine Gliotrophic Factor for Müller Cells under Pathologic Conditions.","date":"2020","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/32945843","citation_count":12,"is_preprint":false},{"pmid":"32927430","id":"PMC_32927430","title":"miR-345-5p regulates adipogenesis via targeting VEGF-B.","date":"2020","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/32927430","citation_count":12,"is_preprint":false},{"pmid":"34719237","id":"PMC_34719237","title":"Elastin-Like Polypeptide: VEGF-B Fusion Protein for Treatment of Preeclampsia.","date":"2021","source":"Hypertension (Dallas, Tex. : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/34719237","citation_count":12,"is_preprint":false},{"pmid":"28771828","id":"PMC_28771828","title":"VEGFB-VEGFR1 ameliorates Ang II-induced cardiomyocyte hypertrophy through Ca2+ -mediated PKG I pathway.","date":"2017","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28771828","citation_count":11,"is_preprint":false},{"pmid":"31730522","id":"PMC_31730522","title":"Effect of ghrelin on VEGF-B and connexin-43 in a rat model of doxorubicin-induced cardiomyopathy.","date":"2019","source":"Journal of basic and clinical physiology and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31730522","citation_count":11,"is_preprint":false},{"pmid":"32897433","id":"PMC_32897433","title":"Gemcitabine potentiates anti-tumor effect of resveratrol on pancreatic cancer via down-regulation of VEGF-B.","date":"2020","source":"Journal of cancer research and clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/32897433","citation_count":10,"is_preprint":false},{"pmid":"40083161","id":"PMC_40083161","title":"VEGF-B is a novel mediator of ER stress which induces cardiac angiogenesis via RGD-binding integrins independent of VEGFR1/NRP activities.","date":"2025","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/40083161","citation_count":9,"is_preprint":false},{"pmid":"22872519","id":"PMC_22872519","title":"VEGF-A and VEGF-B mRNA expression in gastro-oesophageal cancers.","date":"2012","source":"Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico","url":"https://pubmed.ncbi.nlm.nih.gov/22872519","citation_count":9,"is_preprint":false},{"pmid":"23417498","id":"PMC_23417498","title":"VEGF-B expression in colorectal carcinomas and its relevance for tumor progression.","date":"2013","source":"Histology and histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/23417498","citation_count":9,"is_preprint":false},{"pmid":"35912960","id":"PMC_35912960","title":"Long non-coding RNA XIST promotes the malignant features of oral squamous cell carcinoma (OSCC) cells through regulating miR-133a-5p/VEGFB.","date":"2022","source":"Histology and histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/35912960","citation_count":8,"is_preprint":false},{"pmid":"30088238","id":"PMC_30088238","title":"Silencing VEGF-B Diminishes the Neuroprotective Effect of Candesartan Treatment After Experimental Focal Cerebral Ischemia.","date":"2018","source":"Neurochemical research","url":"https://pubmed.ncbi.nlm.nih.gov/30088238","citation_count":8,"is_preprint":false},{"pmid":"39779732","id":"PMC_39779732","title":"Vitamin D and exercise improve VEGF-B production and IGF-1 levels in diabetic rats: insights the role of miR-1 suppression.","date":"2025","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/39779732","citation_count":8,"is_preprint":false},{"pmid":"39215561","id":"PMC_39215561","title":"VEGF-B prevents chronic hyperglycemia-induced retinal vascular leakage by regulating the CDC42-ZO1/VE-cadherin pathway.","date":"2024","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/39215561","citation_count":7,"is_preprint":false},{"pmid":"37724264","id":"PMC_37724264","title":"Clinical efficacy and changes of serum VEGF-A, VEGF-B, and PLGF after conbercept treating neovascular age-related macular degeneration.","date":"2023","source":"International journal of ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/37724264","citation_count":6,"is_preprint":false},{"pmid":"34732848","id":"PMC_34732848","title":"LncRNA TINCR improves cardiac hypertrophy by regulating the miR-211-3p-VEGFB-SDF-1α-CXCR4 pathway.","date":"2021","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/34732848","citation_count":5,"is_preprint":false},{"pmid":"38471613","id":"PMC_38471613","title":"Knockdown of the VEGFB/VEGFR1 signaling suppresses pubertal mammary gland development of mice via the inhibition of PI3K/Akt pathway.","date":"2024","source":"International journal of biological macromolecules","url":"https://pubmed.ncbi.nlm.nih.gov/38471613","citation_count":5,"is_preprint":false},{"pmid":"34679042","id":"PMC_34679042","title":"VEGF-B, VEGF-A, FLT-1, KDR, ERBB2, EGFR, GRB2, RAC1, CDH1 and HYAL-1 Genes Expression Analysis in Canine Mammary Gland Tumors and the Association with Tumor ClinicoPathological Parameters and Dog Breed Assessment.","date":"2021","source":"Veterinary sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34679042","citation_count":5,"is_preprint":false},{"pmid":"34658874","id":"PMC_34658874","title":"A Cyclic Peptide Epitope of an Under-Explored VEGF-B Loop 1 Demonstrated In Vivo Anti-Angiogenic and Anti-Tumor Activities.","date":"2021","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/34658874","citation_count":5,"is_preprint":false},{"pmid":"35660637","id":"PMC_35660637","title":"Role of VEGFB in electrical pulse stimulation inhibits apoptosis in C2C12 myotubes.","date":"2022","source":"Peptides","url":"https://pubmed.ncbi.nlm.nih.gov/35660637","citation_count":4,"is_preprint":false},{"pmid":"38150518","id":"PMC_38150518","title":"Reduction in Insulin Uncovers a Novel Effect of VEGFB on Cardiac Substrate Utilization.","date":"2023","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/38150518","citation_count":4,"is_preprint":false},{"pmid":"25663437","id":"PMC_25663437","title":"Binding of VEGF-A is sufficient to abrogate the disturbing effects of VEGF-B together with VEGF-A on retinal endothelial cells.","date":"2015","source":"Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie","url":"https://pubmed.ncbi.nlm.nih.gov/25663437","citation_count":4,"is_preprint":false},{"pmid":"39859255","id":"PMC_39859255","title":"Neuroprotective Effects of VEGF-B in a Murine Model of Aggressive Neuronal Loss with Childhood Onset.","date":"2025","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/39859255","citation_count":4,"is_preprint":false},{"pmid":"39631591","id":"PMC_39631591","title":"Knockdown of VEGF-B improves HFD-induced insulin resistance by enhancing glucose uptake in vascular endothelial cells via the PI3K/Akt pathway.","date":"2024","source":"International journal of biological macromolecules","url":"https://pubmed.ncbi.nlm.nih.gov/39631591","citation_count":4,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":55825,"output_tokens":8458,"usd":0.147173,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":18411,"output_tokens":6345,"usd":0.12534,"stage2_stop_reason":"end_turn"},"total_usd":0.272513,"stage1_batch_id":"msgbatch_01UT1AahFPCAyn2uVweS7A9z","stage2_batch_id":"msgbatch_01HuKWtKNT4Pqj1bc8eEP5RV","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1998,\n      \"finding\": \"VEGF-B binds selectively to VEGF receptor-1/Flt-1, with binding blockable by excess VEGF indicating at least partially overlapping binding sites. Mutating putative binding determinants Asp63, Asp64, and Glu67 to alanine reduced but did not abolish Flt-1 affinity. Binding of VEGF-B to its receptor on endothelial cells leads to increased expression and activity of urokinase-type plasminogen activator and plasminogen activator inhibitor-1.\",\n      \"method\": \"Receptor binding assay, site-directed mutagenesis, endothelial cell functional assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — receptor binding with mutagenesis plus functional downstream assay in one study; foundational paper replicated in concept by numerous subsequent studies\",\n      \"pmids\": [\"9751730\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"VEGF-B is not regulated by hypoxia, Ras oncoprotein, or mutant p53 (stimuli that potently induce VEGF-A), and its mRNA is highly stable (T1/2 > 8 h), distinguishing its regulation from VEGF-A and VEGF-C.\",\n      \"method\": \"Northern blot, mRNA stability assay in cultured cells\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean cell-based assays with multiple stimuli, single lab\",\n      \"pmids\": [\"9188862\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"The VEGF-B186 isoform arises by alternative splicing introducing a frameshift, is secreted, undergoes O-linked glycosylation post-secretion (25 kDa → 32 kDa), is expressed as a disulfide-linked homodimer, and forms heterodimers with VEGF-A when co-expressed.\",\n      \"method\": \"cDNA cloning, transfection, SDS-PAGE, biochemical characterization\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct biochemical characterization with multiple orthogonal methods (SDS-PAGE, glycosylation analysis, co-expression for heterodimerization)\",\n      \"pmids\": [\"8702615\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Vegfb knockout mice have smaller hearts and dysfunctional coronary vasculature with impaired recovery from experimentally induced myocardial ischemia, establishing a role for VEGF-B in coronary vasculature development and/or function.\",\n      \"method\": \"Gene knockout mouse model, cardiac phenotyping, coronary occlusion model\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean KO with defined cardiac phenotypic readout; replicated and extended by subsequent studies\",\n      \"pmids\": [\"10666423\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"VEGF-B inhibits apoptosis via VEGFR-1-mediated suppression of proapoptotic BH3-only protein genes and other apoptosis/cell-death-related genes (including p53 and caspase family members); neuronal rescue in retinal and brain models was confirmed in vivo.\",\n      \"method\": \"Gene expression profiling, real-time PCR, in vivo neuroprotection models (retinal degeneration, stroke), VEGFR-1-dependent mechanism\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple cell types, in vivo models, receptor-dependency demonstrated; single lab but orthogonal methods\",\n      \"pmids\": [\"18259607\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"VEGF-B is dispensable for blood vessel growth but critical for vascular cell survival (endothelial cells, pericytes, smooth muscle cells, vascular stem/progenitor cells); its vascular survival effect is mediated through both NRP-1 and VEGFR-1 by regulating pro-survival gene expression.\",\n      \"method\": \"Multiple animal models, multiple vascular cell type assays, in vivo choroidal/retinal neovascularization targeting\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple cell types and animal models, two receptors identified, replicated concept across publications\",\n      \"pmids\": [\"19369214\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"VEGF-B186 isoform protects primary motor neurons against degeneration via the tyrosine kinase activity of Flt1 (VEGFR-1) expressed on motor neurons; intracerebroventricular delivery prolonged survival of mutant SOD1 rats. Vegfb-knockout mice crossed with mutant SOD1 mice developed more severe motor neuron degeneration.\",\n      \"method\": \"Primary motor neuron culture, Vegfb/SOD1 double-mutant mice, intracerebroventricular delivery, kinase inhibitor experiments\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vitro + in vivo epistasis + receptor tyrosine kinase dependency established in one study\",\n      \"pmids\": [\"18923022\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"VEGF-B186 activates VEGFR-1 on cardiomyocytes (which also express VEGFR-2 and neuropilin-1; VEGFR-1 is up-regulated under hypoxia/oxidative stress), elicits an antiapoptotic effect, and induces a compensatory hypertrophic gene expression profile (activation of αMHC, repression of βMHC/skeletal α-actin, increase of SERCA2a, RYR, PGC1α), preserving cardiac function after myocardial infarction.\",\n      \"method\": \"AAV-mediated gene delivery in rats, cardiomyocyte culture, gene expression profiling, in vivo myocardial infarction model\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vitro + in vivo, receptor identified, gene expression profile established, functional cardiac readout\",\n      \"pmids\": [\"20019242\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"VEGF-B and its receptor FLT1 are expressed in dorsal root ganglion neurons; VEGF-B186 maintains mitochondrial membrane potential, reduces neuronal stress, and protects against retrograde degeneration of sensory neurons via direct FLT1-mediated effects on neurons (not surrounding vasculature).\",\n      \"method\": \"DRG primary cultures from Vegfb/Flt1 KO mice, paclitaxel neuropathy model, neuronal FLT1 transgenic overexpression, gene transfer, recombinant protein\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic models (KO, transgenic OE), in vitro + in vivo, receptor identified, mitochondrial readout\",\n      \"pmids\": [\"21248239\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"VEGF-B controls endothelial uptake and transport of fatty acids in heart and skeletal muscle. Vegfb knockout in diabetic db/db mice prevented ectopic lipid deposition and increased muscle glucose uptake; pharmacological VEGF-B inhibition restored insulin sensitivity in high-fat-diet rats.\",\n      \"method\": \"Vegfb genetic knockout in db/db mice, antibody pharmacological inhibition, glucose tolerance/insulin sensitivity assays, in vivo imaging\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic and pharmacological inhibition in multiple rodent models with defined metabolic readouts; published in Nature, independently replicated concept\",\n      \"pmids\": [\"23023133\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"VEGFB binding to VEGFR1 activates the VEGF/VEGFR2 pathway and increases capillary density, tissue perfusion, and insulin supply/signaling in adipose tissue; endothelial Flt1 deletion enhances VEGFB effect and activates thermogenic program in subcutaneous adipose tissue.\",\n      \"method\": \"Vegfb gene transduction in mice, endothelial Flt1 conditional knockout, metabolic and vascular phenotyping\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic gain- and loss-of-function with multiple orthogonal readouts, receptor pathway identified\",\n      \"pmids\": [\"27076080\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"PGC-1α together with estrogen-related receptor α (ERR-α) transcriptionally regulates Vegfb expression in skeletal muscle; PGC-1α overexpression increases Vegfb, leading to increased muscular lipid accumulation that is normalized by Vegfb ablation.\",\n      \"method\": \"Muscle-specific PGC-1α transgenic mice, Vegfb knockout crosses, chromatin/transcription factor analysis, metabolic phenotyping\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis with double-mutant rescue, transcriptional regulator identified\",\n      \"pmids\": [\"26822083\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Renal VEGF-B expression correlates with severity of diabetic kidney disease; inhibiting VEGF-B signaling in DKD mouse models reduces renal lipotoxicity, re-sensitizes podocytes to insulin signaling, and prevents renal dysfunction.\",\n      \"method\": \"DKD mouse models, anti-VEGF-B antibody treatment, renal lipid/insulin signaling assays\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — pharmacological inhibition in multiple mouse models with mechanistic readouts (lipid, insulin signaling), published in Cell Metabolism\",\n      \"pmids\": [\"28190774\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"VEGF-B is a potent antioxidant; it upregulates numerous antioxidative genes, particularly Gpx1. Loss of Gpx1 activity largely diminished the antioxidative effect of VEGF-B. The antioxidant function is mediated mainly by VEGFR1; Vegfb deletion causes retinal degeneration, and VEGF-B treatment rescues retinal cells in a retinitis pigmentosa model.\",\n      \"method\": \"Vegfb gene deletion in mice, retinitis pigmentosa model, gene expression profiling, Gpx1 loss-of-function, VEGFR1-dependency assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic models (Vegfb KO, Gpx1 KO) with epistasis, in vivo retinal model, VEGFR1-dependency established\",\n      \"pmids\": [\"30249667\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"VEGF-B signaling impairs recycling of low-density lipoprotein receptor (LDLR) to the plasma membrane, reducing cholesterol uptake and membrane cholesterol loading, which decreases GLUT1-dependent endothelial glucose uptake; inhibiting VEGF-B in vivo reconstitutes membrane cholesterol levels and restores glucose uptake.\",\n      \"method\": \"VEGF-B signaling in endothelial cells, LDLR trafficking assay, membrane cholesterol measurement, GLUT1 functional assay, in vivo inhibition\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — mechanistic pathway (VEGF-B→LDLR recycling→cholesterol→GLUT1) established with multiple orthogonal in vitro and in vivo methods\",\n      \"pmids\": [\"32449307\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"VEGF-B inhibits NAFLD development by blocking lipolysis in white adipose tissue (WAT); adipocyte-specific VEGF-B overexpression worsens NAFLD while adipocyte-specific knockout reduces it, acting through regulation of hormone-sensitive lipase activity and WAT insulin resistance.\",\n      \"method\": \"AdipoqCre conditional VEGF-B transgenic and floxed knockout mice, NAFLD model, neutralizing antibody, lipolysis assay, hormone-sensitive lipase activity\",\n      \"journal\": \"Journal of hepatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-type-specific gain- and loss-of-function with mechanistic effector (HSL) identified, pharmacological validation\",\n      \"pmids\": [\"36717026\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"VEGF-B186 promotes cardiac angiogenesis via RGD-binding integrins (ITGAV and ITGA5) as newly identified receptors, independent of VEGFR1 tyrosine kinase activity or neuropilin binding; this involves induction of ER stress via upregulation of BiP and ER stress sensors (ATF6, PERK, IRE1α), activating the unfolded protein response through XBP1.\",\n      \"method\": \"VEGFR1 TK-/- mice, VEGF-B186R127S NRP-binding mutant, adenoviral gene transfer in mouse hearts, in vitro cardiac endothelial cells, pig and wild-type mouse validation, integrin identification\",\n      \"journal\": \"Molecular therapy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — multiple genetic models (TK-KO, NRP-binding mutant), receptor identification with mechanistic pathway, validated in multiple species; single lab\",\n      \"pmids\": [\"40083161\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"VEGF-B binds to FGFR1, induces FGFR1/VEGFR1 complex formation, and suppresses FGF2-induced Erk activation, thereby inhibiting FGF2-driven angiogenesis and tumor growth when FGF2/FGFR1 levels are high; VEGF-B thus acts as an endogenous inhibitor of angiogenesis under these conditions.\",\n      \"method\": \"In vitro binding assay (VEGF-B to FGFR1), co-immunoprecipitation (FGFR1/VEGFR1 complex), Erk activation assay, in vivo angiogenesis and tumor models\",\n      \"journal\": \"Signal transduction and targeted therapy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — receptor binding, complex formation by Co-IP, downstream signaling assay, in vivo validation in one study\",\n      \"pmids\": [\"37591843\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Vegfb knockout mice show reduced synovial angiogenesis and reduced pathology (swelling, inflammation) in both antigen-induced and collagen-induced arthritis models, implicating VEGF-B in pathological vascular remodeling during inflammatory arthritis.\",\n      \"method\": \"Vegfb-/- mice in two arthritis models, histological scoring, synovial vessel density quantification\",\n      \"journal\": \"Arthritis and rheumatism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean KO in two disease models with defined vascular and inflammatory readouts, single lab\",\n      \"pmids\": [\"13130487\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"VEGF-B stimulates neurogenesis in the adult brain; intracerebroventricular VEGF-B administration increased BrdU incorporation into cells of neuronal lineage in the hippocampal dentate gyrus and forebrain subventricular zone both in vitro and in vivo, and Vegfb-KO mice showed impaired neurogenesis.\",\n      \"method\": \"Vegfb-KO mice, intracerebroventricular injection, BrdU incorporation assay, neuronal marker immunostaining\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO plus gain-of-function rescue, defined neurogenesis readout; single lab\",\n      \"pmids\": [\"16337622\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"RTEF-1 in endothelial cells directly increases VEGF-B promoter activity through a direct interaction (confirmed by ChIP and luciferase assay); endothelium-derived VEGF-B then stimulates hypertrophic gene expression in adjacent cardiomyocytes via ERK1/2, which was abrogated by VEGF-B siRNA.\",\n      \"method\": \"Chromatin immunoprecipitation, luciferase promoter assay, siRNA knockdown, cardiomyocyte conditioned medium experiments, VE-Cad/RTEF-1 transgenic mice\",\n      \"journal\": \"Cardiovascular research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct promoter interaction by ChIP/luciferase, paracrine mechanism by siRNA rescue; single lab\",\n      \"pmids\": [\"21169295\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"VEGFB expression is found in cardiomyocytes with a postnatal ventricular shift, while VEGFR1 expression is restricted to endothelial cells in heart, lung, and kidney, supporting a tightly controlled paracrine signaling mechanism; reduced VEGFR1 expression resulted in decreased cardiac fatty acid accumulation and increased peripheral insulin sensitivity.\",\n      \"method\": \"β-galactosidase knock-in reporter mice, immunofluorescence microscopy, Flt1 heterozygous metabolic phenotyping\",\n      \"journal\": \"Cell and tissue research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reporter gene localization plus functional metabolic phenotype; single lab\",\n      \"pmids\": [\"26928042\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"In the diabetic heart, surface-bound VEGFB on cardiomyocytes is released by endothelial heparanase secretion; high glucose and heparanase trigger VEGFB release, which then acts on endothelial cells (autocrine) and cardiomyocytes (paracrine) to promote survival via ERK signaling. Under hyperglycemia, VEGFB production is impaired and VEGFR1 expression is compensatorily increased.\",\n      \"method\": \"Diabetic heart models, heparanase secretion experiments, ERK signaling assays, gene expression analysis\",\n      \"journal\": \"American journal of physiology. Heart and circulatory physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — bidirectional signaling mechanism identified with cell/molecular assays; single lab, limited receptor-specific genetic tools used\",\n      \"pmids\": [\"28314760\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Exogenous VEGF-B promotes diabetic corneal nerve fiber regeneration through reactivation of PI3K/Akt-GSK3β-mTOR signaling and attenuation of neuronal mitochondrial dysfunction via VEGF receptor-1 and neuropilin-1; VEGF-B also elevated corneal pigment epithelial-derived factor (PEDF), and PEDF blockade partially abolished VEGF-B trophic effects.\",\n      \"method\": \"Type 1 diabetic mouse model, trigeminal ganglion cultures, VEGFR-1/NRP-1 pathway analysis, PEDF blocking antibody\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro and in vivo, two receptors identified, downstream signaling defined, partial receptor blockade validation; single lab\",\n      \"pmids\": [\"28091556\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"VEGF-B promotes the formation of endocardium-derived coronary vessels during cardiac development; in adult mice, VEGF-B gene transfer induces endothelial proliferation predominantly in subendocardial coronary vessels and promotes endocardium-derived vessel development into myocardium after infarction.\",\n      \"method\": \"VEGF-B transgenic mice and rats, Vegfb-gene-deleted mice/rats, lineage tracing (apelin-CreERT, NPR3-CreERT), AAV gene transfer, histology, single-cell RNA-seq, microCT\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic gain- and loss-of-function with lineage tracing and multiple orthogonal imaging/molecular methods; published in Circulation\",\n      \"pmids\": [\"33203221\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"VEGFB promotes C2C12 myoblast proliferation and differentiation through VEGFR1-PI3K/Akt (and PI3K/Akt/mTOR for differentiation); VEGFR1 knockdown abolished VEGFB-stimulated proliferation and differentiation, and NRP1 knockdown did not affect differentiation.\",\n      \"method\": \"C2C12 myoblast cell line, VEGFR1/NRP1 siRNA knockdown, PI3K/Akt inhibitors, proliferation and differentiation assays\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — receptor-specific knockdown, pathway inhibitors, two functional readouts; single lab\",\n      \"pmids\": [\"34948148\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"VEGF-B is expressed in Müller cells and acts as an autocrine gliotrophic factor under pathologic conditions (hypoxia, oxidative stress); VEGF-B neutralization under pathologic conditions enhanced Müller cell death and decreased Kir4.1 and aquaporin-4 expression, while recombinant VEGF-B restored glutamine synthetase and normalized TRPV4 channel expression and activity.\",\n      \"method\": \"Human and mouse Müller cell lines and primary cells, RT-PCR, ELISA, Western blot, VEGF-B neutralization, calcium imaging (Fura-2)\",\n      \"journal\": \"Investigative ophthalmology & visual science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — autocrine mechanism with neutralization and recombinant protein rescue, multiple functional readouts; single lab\",\n      \"pmids\": [\"32945843\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"VEGF-B gene therapy prevented doxorubicin-induced cardiac atrophy, capillary rarefaction, and endothelial apoptosis; VEGF-B promoted coronary arteriogenesis and physiological cardiac hypertrophy, and protected cultured endothelial cells from apoptosis restoring tube formation.\",\n      \"method\": \"AAV gene therapy in tumor-bearing mice, endothelial cell culture, apoptosis assay, tube formation assay, cardiac function by echocardiography\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo gene therapy plus in vitro mechanistic validation with multiple readouts; single lab\",\n      \"pmids\": [\"27799559\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"VEGFB-VEGFR1 signaling prevents Ang II-induced cardiomyocyte hypertrophy via Ca2+-mediated PKG I pathway; VEGFB reduced Ang II-induced Ca2+ elevation, prevented increases in β-MHC/BNP/ANP, and maintained PKG I/p-VASP/RGS2; VEGFR1 knockdown partially reversed these effects.\",\n      \"method\": \"H9C2 cardiomyocyte cell line, Ang II stimulation, VEGFR1 siRNA knockdown, Ca2+ measurement, PKG I/p-VASP/RGS2 Western blot\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — receptor-specific knockdown, Ca2+ and PKG pathway established; single lab, cell line only\",\n      \"pmids\": [\"28771828\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"High-dose VEGF-B overexpression in the heart induces sympathetic nerve sprouting (increased nerve density ~2-fold) via a VEGFR-1 signaling-independent mechanism, upregulating Nr4a2, ATF6, and MANF, and leading to increased risk of ventricular arrhythmias and sudden cardiac death.\",\n      \"method\": \"αMHC-VEGF-B transgenic mice, adenoviral VEGF-B186 pig cardiac gene transfer, immunostaining for nerve density, dobutamine stress testing, gene expression analysis, survival analysis\",\n      \"journal\": \"Molecular therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two species, transgenic and gene transfer models, VEGFR1-independence noted, nerve sprouting mechanism identified; single lab\",\n      \"pmids\": [\"32243833\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Autocrine VEGF-B signaling in activated T cells controls lipid synthesis and mitochondrial inner membrane integrity (cardiolipin maintenance) for T cell survival; disruption of VEGF-B signaling reduced cardiolipin mass, increased apoptosis, and reduced memory T cell development. Mechanistically, VEGF-B signaling through GABPα induces SENP2 expression, which de-SUMOylates PPARγ to enhance phospholipid synthesis.\",\n      \"method\": \"T cell-specific VEGF-B disruption, cardiolipin mass spectrometry, apoptosis assays, memory T cell flow cytometry, GABPα/SENP2/PPARγ molecular pathway analysis\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic disruption plus defined molecular pathway (GABPα→SENP2→deSUMOylation of PPARγ→cardiolipin), multiple orthogonal readouts; published in JCI\",\n      \"pmids\": [\"39145452\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"VEGF-B prevents hyperglycemia-induced retinal vascular leakage by upregulating CDC42/ZO1/VE-cadherin expression; VEGF-B knockdown increased hyperglycemia-induced vascular leakage in human retinal endothelial cells, while VEGF-B overexpression or intravitreal injection restored CDC42/ZO1/VE-cadherin and reduced leakage.\",\n      \"method\": \"STZ-induced diabetic mouse model, VEGF-B knockdown/overexpression in HRECs, label-free proteomics, Western blot, whole-mount staining, intravitreal injection\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro and in vivo, defined pathway (CDC42-ZO1/VE-cadherin), proteomic discovery with validation; single lab\",\n      \"pmids\": [\"39215561\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Cardiac-specific VEGFB overexpression reduces lipoprotein lipase (LPL) activity at the coronary lumen through multiple regulatory mechanisms, lowers accumulation of lipid intermediates (diacylglycerols, lysophosphatidylcholine), and improves cardiac insulin sensitivity.\",\n      \"method\": \"Cardiomyocyte-specific VEGFB transgenic rats, RNA sequencing, Langendorff heart LPL activity assay, untargeted metabolomics, insulin sensitivity assay, high-resolution respirometry\",\n      \"journal\": \"American journal of physiology. Endocrinology and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cardiac transgenic model with multi-omic readouts and direct LPL activity measurement; single lab\",\n      \"pmids\": [\"34747201\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"VEGF-B is expressed predominantly in the developing myocardium (not endothelial cells), while its receptor VEGFR-1 is almost exclusively present in endothelial cells, supporting a paracrine mode of action in vascular development.\",\n      \"method\": \"In situ hybridization and immunohistochemistry in mouse embryos (E8.5–E17.5)\",\n      \"journal\": \"Developmental dynamics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — direct localization by two independent methods across developmental stages; functional paracrine inference from localization data\",\n      \"pmids\": [\"10340753\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"VEGF-B is a secreted disulfide-linked homodimer (with two alternative isoforms, VEGF-B167 and VEGF-B186) that signals primarily through VEGFR1/Flt-1 (and neuropilin-1), and has been mechanistically established to: (1) regulate endothelial fatty acid uptake/transport by controlling lipid transporter expression and LDLR recycling/membrane cholesterol, thereby controlling tissue lipid accumulation and contributing to metabolic disease; (2) promote cell survival and inhibit apoptosis by suppressing BH3-only protein gene expression downstream of VEGFR1, protecting vascular cells, neurons, and cardiomyocytes; (3) upregulate antioxidant defenses (particularly Gpx1) via VEGFR1; (4) activate VEGFR1 on cardiomyocytes to induce compensatory hypertrophy, arteriogenesis, and endocardium-derived coronary vessel formation; (5) promote cardiac angiogenesis through RGD-binding integrins (ITGAV/ITGA5) and ER stress/UPR independently of VEGFR1 kinase activity; (6) bind FGFR1, induce FGFR1/VEGFR1 complexes, and suppress FGF2-driven angiogenesis when FGF2/FGFR1 levels are high; (7) support T cell survival through autocrine signaling via GABPα/SENP2/PPARγ-mediated cardiolipin synthesis; and (8) regulate vascular integrity in the retina through the CDC42-ZO1/VE-cadherin pathway, while being dispensable for developmental blood vessel growth but critical for vascular cell survival.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"VEGF-B is a secreted disulfide-linked homodimer that exists as two alternatively spliced isoforms (VEGF-B167 and VEGF-B186), the latter O-glycosylated post-secretion and capable of forming heterodimers with VEGF-A [#2]. Unlike VEGF-A, its expression is not induced by hypoxia, Ras, or mutant p53 and its mRNA is unusually stable, marking it as a constitutive rather than stress-inducible angiogenic factor [#1]. It signals chiefly by binding VEGFR-1/Flt-1 and neuropilin-1 in a paracrine arrangement, where ligand is produced by myocardium while receptor is restricted to endothelium [#0, #33, #5]. Two dominant functional themes emerge. First, VEGF-B is a survival and cytoprotective factor: through VEGFR-1 it suppresses pro-apoptotic BH3-only genes and other death-related genes to protect endothelial cells, pericytes, neurons, and cardiomyocytes [#4, #5], protects motor and sensory neurons via neuronal Flt-1 tyrosine kinase activity and mitochondrial maintenance [#6, #8], and upregulates antioxidant defenses—particularly Gpx1—to rescue degenerating retina [#13]. Second, VEGF-B is a central regulator of tissue lipid handling and metabolism: it controls endothelial fatty acid uptake/transport such that its inhibition prevents ectopic lipid deposition and restores insulin sensitivity in diabetic models [#10], is transcriptionally driven by PGC-1\\u03b1/ERR-\\u03b1 in muscle [#11], impairs LDLR recycling to lower membrane cholesterol and GLUT1-dependent glucose uptake [#14], and modulates adipose lipolysis through hormone-sensitive lipase to influence NAFLD [#15]. In the heart, VEGF-B activates VEGFR-1 on cardiomyocytes to drive compensatory hypertrophy, arteriogenesis, and endocardium-derived coronary vessel formation [#7, #24], while VEGF-B186 can also promote cardiac angiogenesis through RGD-binding integrins (ITGAV/ITGA5) and ER-stress/UPR signaling independently of VEGFR-1 kinase activity [#16]. VEGF-B additionally engages FGFR1, inducing FGFR1/VEGFR1 complexes that suppress FGF2-driven angiogenesis under high FGF2/FGFR1 conditions, positioning it as a context-dependent endogenous angiogenesis inhibitor [#17]. VEGF-B is dispensable for developmental blood vessel growth but is required for vascular cell survival and integrity [#5, #31].\",\n  \"teleology\": [\n    {\n      \"year\": 1996,\n      \"claim\": \"Established the molecular identity and biochemistry of VEGF-B, defining isoforms, dimerization, and heterodimer potential with VEGF-A — the structural foundation for all downstream signaling work.\",\n      \"evidence\": \"cDNA cloning, transfection, SDS-PAGE and glycosylation analysis of VEGF-B186\",\n      \"pmids\": [\"8702615\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor and downstream signaling not yet defined\", \"Functional difference between isoforms unresolved\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Identified VEGFR-1/Flt-1 as the receptor and showed receptor engagement drives a pro-fibrinolytic endothelial program, while a separate study established that VEGF-B regulation is fundamentally distinct from the hypoxia-driven VEGF-A.\",\n      \"evidence\": \"Receptor binding assay with site-directed mutagenesis plus endothelial functional readout; Northern blot and mRNA stability assays\",\n      \"pmids\": [\"9751730\", \"9188862\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo physiological role not established\", \"Downstream signaling cascade beyond uPA/PAI-1 unknown\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Defined the paracrine architecture: ligand in myocardium, receptor in endothelium, framing VEGF-B as a cardiac-vascular paracrine signal.\",\n      \"evidence\": \"In situ hybridization and immunohistochemistry across mouse embryonic stages\",\n      \"pmids\": [\"10340753\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Paracrine function inferred from localization, not functionally tested here\", \"Adult expression pattern not addressed\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"First loss-of-function evidence linked VEGF-B to coronary vasculature and recovery from cardiac ischemia, moving it from biochemistry to physiology.\",\n      \"evidence\": \"Vegfb knockout mice with cardiac phenotyping and coronary occlusion model\",\n      \"pmids\": [\"10666423\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cellular mechanism (survival vs growth) unresolved\", \"Receptor-dependence in vivo not dissected\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Extended VEGF-B to pathological vascular remodeling, showing it drives synovial angiogenesis and inflammation in arthritis.\",\n      \"evidence\": \"Vegfb-/- mice in antigen- and collagen-induced arthritis with histological and vessel-density scoring\",\n      \"pmids\": [\"13130487\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of synovial angiogenesis not defined\", \"Receptor and cell-type specificity unknown\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Defined the core cytoprotective mechanism — VEGFR-1-dependent suppression of BH3-only pro-apoptotic genes — and demonstrated neuroprotection in vivo, recasting VEGF-B as a survival factor rather than a growth factor.\",\n      \"evidence\": \"Gene expression profiling, qPCR, and in vivo retinal/stroke neuroprotection models\",\n      \"pmids\": [\"18259607\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signaling intermediates from VEGFR-1 to gene suppression not mapped\", \"Cell-type generality not yet tested\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Established that VEGF-B is dispensable for vessel growth but essential for vascular cell survival via NRP-1 and VEGFR-1, and that VEGF-B186 protects motor neurons through neuronal Flt-1 tyrosine kinase activity.\",\n      \"evidence\": \"Multiple vascular cell assays and animal models; primary motor neuron cultures, Vegfb/SOD1 double mutants, ICV delivery, kinase inhibitors\",\n      \"pmids\": [\"19369214\", \"18923022\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contributions of NRP-1 vs VEGFR-1 not quantified\", \"Downstream survival effectors in neurons not fully defined\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Showed VEGF-B186 directly acts on cardiomyocytes through VEGFR-1 to elicit antiapoptotic and compensatory hypertrophic transcriptional programs preserving post-infarct cardiac function.\",\n      \"evidence\": \"AAV gene delivery in rats, cardiomyocyte culture, gene expression profiling, MI model\",\n      \"pmids\": [\"20019242\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Long-term safety of induced hypertrophy not assessed\", \"Endothelial vs cardiomyocyte contributions not separated\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Demonstrated direct neuronal action on sensory neurons via FLT1 with mitochondrial membrane potential maintenance, distinguishing neuronal from vascular protection.\",\n      \"evidence\": \"DRG cultures from Vegfb/Flt1 KO mice, paclitaxel neuropathy model, neuronal FLT1 transgenics, recombinant protein\",\n      \"pmids\": [\"21248239\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism coupling FLT1 to mitochondrial integrity unresolved\", \"Translation to human neuropathy untested\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Established VEGF-B as a master regulator of endothelial fatty acid uptake, linking it to ectopic lipid deposition, insulin resistance, and metabolic disease — a major functional pivot.\",\n      \"evidence\": \"Vegfb knockout in db/db mice and antibody inhibition in HFD rats with metabolic readouts\",\n      \"pmids\": [\"23023133\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of regulated lipid transporters not fully defined here\", \"Tissue-specific versus systemic effects unresolved\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Mapped upstream transcriptional control (PGC-1\\u03b1/ERR-\\u03b1) of Vegfb in muscle and showed VEGFB-VEGFR1 signaling activates VEGF/VEGFR2-dependent angiogenesis to improve adipose perfusion and insulin supply, while reporter studies confirmed the cardiomyocyte-to-endothelium paracrine axis.\",\n      \"evidence\": \"PGC-1\\u03b1 transgenic and Vegfb KO crosses; Vegfb gene transduction with endothelial Flt1 cKO; \\u03b2-gal knock-in reporter mice and Flt1 heterozygote phenotyping\",\n      \"pmids\": [\"26822083\", \"27076080\", \"26928042\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Reconciliation of VEGFB as both lipid-uptake promoter and perfusion enhancer not fully integrated\", \"Crosstalk to VEGFR2 mechanism not molecularly resolved\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Extended the metabolic role to diabetic kidney disease, showing VEGF-B inhibition reduces renal lipotoxicity and restores podocyte insulin signaling, with parallel work defining diabetic-heart heparanase-triggered VEGFB release and PEDF-dependent corneal nerve regeneration.\",\n      \"evidence\": \"DKD mouse models with anti-VEGF-B antibody; diabetic heart heparanase secretion and ERK assays; diabetic corneal nerve model with VEGFR-1/NRP-1 and PEDF blockade\",\n      \"pmids\": [\"28190774\", \"28314760\", \"28091556\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor-specific genetic dissection limited in heparanase study\", \"Whether renal and cardiac effects share a common transporter mechanism unknown\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identified VEGF-B as a potent antioxidant acting mainly through VEGFR-1 and Gpx1, providing a redox-based arm of its cytoprotection in the retina.\",\n      \"evidence\": \"Vegfb and Gpx1 KO mice with epistasis, retinitis pigmentosa model, expression profiling\",\n      \"pmids\": [\"30249667\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signaling linking VEGFR-1 to antioxidant gene induction not mapped\", \"Generality beyond retina untested\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Resolved a key metabolic mechanism — VEGF-B impairs LDLR recycling to reduce membrane cholesterol and GLUT1-dependent glucose uptake — and demonstrated VEGF-B drives endocardium-derived coronary vessel formation, while autocrine VEGF-B sustains Müller glia and high-dose cardiac VEGF-B triggers VEGFR-1-independent sympathetic nerve sprouting with arrhythmia risk.\",\n      \"evidence\": \"Endothelial LDLR trafficking and cholesterol/GLUT1 assays with in vivo inhibition; lineage tracing and scRNA-seq in VEGF-B transgenic/KO hearts; Müller cell neutralization/rescue; \\u03b1MHC-VEGF-B transgenic and pig gene transfer\",\n      \"pmids\": [\"32449307\", \"33203221\", \"32945843\", \"32243833\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor identity for nerve-sprouting and gliotrophic effects not fully defined\", \"Dose threshold for beneficial vs arrhythmogenic cardiac effects unclear\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Defined VEGFB-VEGFR1-PI3K/Akt control of myoblast proliferation/differentiation and cardiomyocyte-specific metabolic and anti-hypertrophic effects, including reduced coronary LPL activity and protection against Ang II hypertrophy via Ca2+/PKG I.\",\n      \"evidence\": \"C2C12 receptor knockdown and pathway inhibitors; cardiac transgenic rats with multi-omics and LPL activity; H9C2 Ang II model with VEGFR1 knockdown and PKG pathway analysis\",\n      \"pmids\": [\"34948148\", \"34747201\", \"28771828\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cell-line-based findings need in vivo confirmation\", \"Integration of metabolic and anti-hypertrophic effects mechanistically incomplete\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Uncovered context-dependent angiogenesis inhibition via FGFR1 binding and FGFR1/VEGFR1 complex formation suppressing FGF2/Erk signaling, and defined an adipose lipolysis mechanism (HSL) by which VEGF-B influences NAFLD.\",\n      \"evidence\": \"In vitro binding, Co-IP, Erk assays and in vivo tumor/angiogenesis models; adipocyte-specific VEGF-B transgenic/KO mice with lipolysis and HSL assays\",\n      \"pmids\": [\"37591843\", \"36717026\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of FGFR1/VEGFR1 complex unresolved\", \"How VEGF-B switches between pro- and anti-angiogenic roles in vivo unclear\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Revealed an autocrine immunometabolic role: VEGF-B sustains T cell survival and memory via a GABP\\u03b1\\u2192SENP2\\u2192PPAR\\u03b3 deSUMOylation axis driving cardiolipin synthesis, and a retinal vascular-integrity role via the CDC42/ZO1/VE-cadherin pathway.\",\n      \"evidence\": \"T cell-specific VEGF-B disruption with cardiolipin mass spec and GABP\\u03b1/SENP2/PPAR\\u03b3 analysis; STZ diabetic mice and HREC knockdown/overexpression with proteomics\",\n      \"pmids\": [\"39145452\", \"39215561\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor mediating T cell autocrine signaling not specified\", \"Link between barrier integrity pathway and canonical VEGFR-1 signaling unresolved\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identified RGD-binding integrins ITGAV and ITGA5 as new VEGF-B186 receptors mediating cardiac angiogenesis through ER stress/UPR, independent of VEGFR-1 kinase activity, expanding the receptor repertoire beyond Flt-1.\",\n      \"evidence\": \"VEGFR1 TK-KO mice, NRP-binding mutant, adenoviral cardiac gene transfer, cardiac endothelial cells, multi-species validation, integrin identification\",\n      \"pmids\": [\"40083161\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative in vivo contribution of integrin vs VEGFR-1 pathways not quantified\", \"Structural basis of integrin engagement unresolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How VEGF-B integrates its multiple receptors (VEGFR-1, NRP-1, FGFR1, RGD-integrins) into context-specific outputs — survival, lipid handling, angiogenesis promotion vs inhibition — remains unresolved at the level of a unified signaling logic.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model of VEGF-B with its non-Flt1 receptors\", \"Determinants selecting between pro- and anti-angiogenic outcomes unknown\", \"Receptor usage in immune and metabolic contexts not fully mapped\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 5, 7, 16, 17]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [4, 13, 17]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [2, 0]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 7, 25, 28]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [10, 11, 14, 15, 32]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [4, 5]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [13, 16]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [3, 24, 33]}\n    ],\n    \"complexes\": [\"FGFR1/VEGFR1 complex\"],\n    \"partners\": [\"FLT1\", \"NRP1\", \"FGFR1\", \"ITGAV\", \"ITGA5\", \"VEGFA\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}